Recent Advances in Management of Vitiligo.

Area of Science:

• Dermatology
• Immunology
• Genetics

Background:

• Vitiligo is an acquired skin disorder affecting 0.5%-2% globally, characterized by melanocyte loss and depigmented macules.
• The condition significantly impacts patients' psychosocial well-being, leading to diminished self-esteem and social ostracization.
• Current treatments include topical therapies, phototherapy, and systemic immunomodulators.

Purpose of the Study:

• To review traditional and novel therapeutic options for vitiligo.
• To explore recent insights into the pathogenesis of vitiligo, including genetic, autoimmune, and environmental factors.
• To highlight emerging treatment modalities targeting molecular pathways.

Main Methods:

• Literature review of traditional and novel vitiligo treatments.
• Analysis of recent research on vitiligo pathogenesis.
• Discussion of emerging therapies targeting JAK-STAT pathway, melanocortin-1 receptor, and immune checkpoints.

Main Results:

• Traditional treatments include corticosteroids, calcineurin inhibitors, and phototherapy.
• Novel therapies target specific molecular pathways to combat autoimmunity and enhance melanocyte function.
• Emerging treatments show encouraging results, but literature is limited and efficacy varies.

Conclusions:

• Vitiligo management is advancing with new treatment strategies and a deeper understanding of its pathophysiology.
• Novel therapies offer hope for improved patient outcomes and quality of life.
• Continued research in genetics and pathophysiology is crucial for effective vitiligo treatment.